Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8441385 | European Journal of Cancer | 2016 | 12 Pages |
Abstract
There is no overall difference in HRQOL between SC and LC neoadjuvant treatment strategies, in the first 12 months, after surgery. In the immediate postoperative period HRQOL was adversely affected in both groups but for the most part was temporary. Some residual sexual functioning concerns persisted at 12 months.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sue-Anne McLachlan, Richard J. Fisher, John Zalcberg, Michael Solomon, Bryan Burmeister, David Goldstein, Trevor Leong, Stephen P. Ackland, Joseph McKendrick, Bev McClure, John Mackay, Samuel Y. Ngan,